Hospices Civils de Lyon (HCL) and bioMérieux will inaugurate today the “HCL-bioMérieux” joint unit dedicated to research in immunogenomics and inflammation. The unit is headed by Prof. Pierre Miossec and Bruno Mougin.
Chinese Academy of Medical Sciences and bioMerieux join resources to fight emerging pathogens
11 Marzo, 2005
The Chinese Academy of Medical Sciences and bioMérieux announce that they have signed a strategic teaming agreement, aiming at initiating R&D projects in the fields of emerging pathogens. The aim of the project, signed on March 10th, is the creation of a joint Research Lab in Beijing, interacting with Chinese Academy of Medical Sciences.
bioMérieux innovates in food quality testing
31 Gennaio, 2005
bioMérieux launches VITEK® 2 Compact to complete its VITEK 2 range
06 Gennaio, 2005
A world leader in the field of in vitro diagnostics, bioMérieux SA (Euronext: FR0010096479 – BIM) completes its VITEK® 2 range of automated microbial identification and susceptibility testing systems through the launch of VITEK 2 Compact. VITEK 2 Compact is powered by the Advanced Expert System (AES™) software, which validates and interprets susceptibility test results, and detects antibiotic resistance mechanisms.
bioMérieux acquires an option to license Applied NeuroSolutions’ Technology to diagnose Alzheimer’s disease
15 Dicembre, 2004
bioMérieux SA (Euronext: FR0010096479 – BIM) , announces today that it signed a non-exclusive agreement with Applied Neurosolutions granting bioMérieux SA an option to assess Applied Neurosolutions’ technology for the diagnosis of Alzheimer’s disease.
bioMérieux reveals VIDIA, its new automated immunoanalyser, in Paris at the Journées Internationales de Biologie
05 Novembre, 2004
A major player in the in vitro diagnostics marketplace, bioMérieux announces the first official presentation of its new fully automated immunoanalyser, VIDIA®. The system will be presented to healthcare professionals at the Journées Internationales de Biologie held in Paris from November 4 - 6, 2004.
VIDAS® D-Dimer Exclusion™ test from bioMérieux for reliable exclusion of pulmonary embolism and deep vein thrombosis
23 Luglio, 2004
bioMérieux announces that its D-dimer assay, VIDAS D-Dimer Exclusion, is now cleared by the U.S. Food and Drug Administration (FDA) to exclude both pulmonary embolism (PE) and deep vein thrombosis (DVT) as a diagnosis in outpatients. VIDAS D-Dimer Exclusion is the first and only D-dimer assay to be cleared for exclusion of both conditions -- with no further testing -- when used in conjunction with a pre-test probability (PTP) assessment, in low-to-moderate probability outpatients.
NucliSens® easyMAG™ – new innovation from bioMérieux for nucleic acid extraction
07 Giugno, 2004
A world leader in the field of in vitro diagnostics, bioMérieux announces the launch of its new automated sample preparation platform for the extraction of nucleic acid in molecular diagnostics assays. The NucliSens easyMAG system is the latest innovation in bioMérieux’s range of molecular diagnostic solutions
bioMérieux laboratories grant license to Eppendorf for One Step RT-PCR technology
13 Maggio, 2004
Eppendorf AG, Germany, and bioMérieux, France, have concluded a non-exclusive licensing agreement for Eppendorf products using bioMérieux's exclusively controlled One Step RT-PCR technology.
VIDAS® D-Dimer Exclusion test from bioMérieux for reliable exclusion of venous thromboembolism
06 Maggio, 2004
bioMérieux announces that following prospective management studies on its VIDAS D-Dimer test resulting in FDA approval and CE marking, the VIDAS D-Dimer New test has been renamed VIDAS D-Dimer Exclusion™. This name change will more accurately reflect the new intended use of the VIDAS D-Dimer Exclusion test, and also reinforce awareness of the significant role D-dimers can play in exclusion strategies for thromboembolic disease.